Oncolytic viruses driven by tumor-specific promoters

Current Cancer Drug Targets

Volumn 7, Issue 2, 2007, Pages 181-189

  Hardcastle, Jayson ^a   Kurozumi, Kazuhiko ^a   Chiocca, E Antonio ^a   Kaur, Balveen ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

Adenovirus; Cancer; HSV 1; Oncolytic viruses; Promoter; Transcriptional regulation

Indexed keywords

AD MTERT DELTA 19; ALBUMIN; ALPHA FETOPROTEIN; CARCINOEMBRYONIC ANTIGEN; CEA GAMMA 34 5; CEAICP4; CRAD S L; CRAD S S; CV 706; CV 764; CV 787; CV 890; DVM 34 5; G 207; G 92A; NESTIN; ONCOLYTIC HERPES VIRUS; ONCOLYTIC VIRUS; PROSTATE SPECIFIC ANTIGEN; PROTEIN MYB; RQNESTIN 34 5; SURVIVIN; TELOMERASE; TUMOR PROMOTER; UNCLASSIFIED DRUG;

CANCER CELL DESTRUCTION; CLINICAL TRIAL; COLON CANCER; DRUG POTENTIATION; EMBRYO DEVELOPMENT; GENE EXPRESSION; GENE MUTATION; GLIOMA; HUMAN; HYPOXIA; LEIOMYOSARCOMA; LIVER CELL CARCINOMA; MALIGNANT NEOPLASTIC DISEASE; MOLECULAR GENETICS; NONHUMAN; PANCREAS CANCER; PROSTATE CANCER; PROTEIN SYNTHESIS; REVIEW; TRANSCRIPTION REGULATION; UNSPECIFIED SIDE EFFECT; UTERINE CERVIX CANCER; VIRUS REPLICATION; VIRUS VIRULENCE;

ADENOVIRIDAE; ALBUMINS; ALPHA-FETOPROTEINS; ANIMALS; ANOXIA; ANTIGENS, NEOPLASM; CALCIUM-BINDING PROTEINS; CELL CYCLE PROTEINS; DNA-BINDING PROTEINS; HERPESVIRUS 1, HUMAN; HUMANS; INTERMEDIATE FILAMENT PROTEINS; MICROFILAMENT PROTEINS; MICROTUBULE-ASSOCIATED PROTEINS; MUCINS; NEOPLASM PROTEINS; NEOPLASMS; NERVE TISSUE PROTEINS; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; PROMOTER REGIONS (GENETICS); PROSTATE-SPECIFIC ANTIGEN; RNA-BINDING PROTEINS; TELOMERASE; TRANS-ACTIVATORS; TRANSCRIPTION, GENETIC; VIRUS REPLICATION;

EID: 33847378926     PISSN: 15680096     EISSN: None     Source Type: Journal    
DOI: 10.2174/156800907780058880     Document Type: Review

References (93)

1. Ring, C. J. Cytolytic viruses as potential anti-cancer agents. J. Gen. Virol. 2002, 83, 491-502.
2. Chiocca, E. A. Oncolytic viruses. Nat. Rev. Cancer 2002, 2, 938-950.
3. Fulci, G.; Chiocca, E. A. Oncolytic viruses for the therapy of brain tumors and other solid malignancies: A review. Front. Biosci. 2003, 8, e346-e360.
4. Mathis, J. M.; Stoff-Khalili, M. A.; Curiel, D. T. Oncolytic adenoviruses - selective retargeting to tumor cells. Oncogene 2005, 24, 7775-7791.
5. Ikeda, M. A.; Nevins, J. R. Identification of distinct roles for separate E1A domains in disruption of E2F complexes. Mol. Cell Biol. 1993, 13, 7029-7035.
6. Rao, L.; Debbas, M.; Sabbatini, P.; Hockenbery, D.; Korsmeyer, S.; White, E. The adenovirus E1A proteins induce apoptosis, which is inhibited by the E1B 19-kDa and Bcl-2 proteins. Proc. Natl. Acad. Sci. USA 1992, 89, 7742-7746.
7. Argnani, R.; Lufino, M.; Manservigi, M.; Manservigi, R. Replication-competent herpes simplex vectors: design and applications. Gene Ther. 2005, 12(Suppl. 1), S170-S177.
8. Roizman, B.; Knipe, D. M. Herpes simplex viruses and their replication. In Fundamental virology; Fourth ed.; Knipe, D. M.; Howley, P. M.; Eds.; Philadelphia: Lippincott Williams & Wilkins, 2001, pp. 1123-1184.
9. Broberg, E. K.; Hukkanen, V. Immune response to herpes simplex virus and gamma134.5 deleted HSV vectors. Curr. Gene Ther. 2005, 5, 523-530.
10. Kesari, S.; Lee, V. M.; Brown, S. M.; Trojanowski, J. Q.; Fraser, N. W. Selective vulnerability of mouse CNS neurons to latent infection with a neuroattenuated herpes simplex virus-1. J. Neurosci. 1996, 16, 5644-5653.
11. Lou, E. Oncolytic viral therapy and immunotherapy of malignant brain tumors: two potential new approaches of translational research. Ann. Med. 2004, 36, 2-8.
12. Mineta, T.; Rabkin, S. D.; Yazaki, T.; Hunter, W. D.; Martuza, R. L. Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat. Med. 1995, 1, 938-943.
13. Goldstein, D. J.; Weller, S. K. Herpes simplex virus type 1-induced ribonucleotide reductase activity is dispensable for virus growth and DNA synthesis: Isolation and characterization of an ICP6 lacZ insertion mutant. J. Virol. 1988, 62, 196-205.
14. Mineta, T.; Rabkin, S. D.; Martuza, R. L. Treatment of malignant gliomas using ganciclovir-hypersensitive, ribonucleotide reductase-deficient herpes simplex viral mutant. Cancer Res. 1994, 54, 3963-3966.
15. Smith, C. A.; Bates, P.; Rivera-Gonzalez, R.; Gu, B. Deluca, N. A. ICP4, the major transcriptional regulatory protein of herpes simplex virus type 1, forms a tripartite complex with TATA-binding protein and TFIIB. J. Virol. 1993, 67, 4676-4687.
16. Lawler, S. E.; Peruzzi, P. P.; Chiocca, E. A. Genetic strategies for brain tumor therapy. Cancer Gene Ther. 2005, 13, 225-233.
17. Varghese, S.; Rabkin, S. D. Oncolytic herpes simplex virus vectors for cancer virotherapy. Cancer Gene Ther. 2002, 9, 967-978.
18. Folkman, J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 1971, 285, 1182-1186.
19. Jain, R. K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005, 307, 58-62.
20. Brown, J. M. Exploiting the hypoxic cancer cell: mechanisms and therapeutic strategies. Mol. Med. Today 2000, 6, 157-162.
21. Pipiya, T.; Sauthoff, H.; Huang, Y. Q.; Chang, B.; Cheng, J.; Heitner, S.; Chen, S.; Rom, W. N.; Hay, J. G. Hypoxia reduces adenoviral replication in cancer cells by downregulation of viral protein expression. Gene Ther. 2005, 12, 911-917.
22. Shen, B. H.; Hermiston, T. W. Effect of hypoxia on Ad5 infection, transgene expression and replication. Gene Ther. 2005, 12, 902-910.
23. Wang, G. L.; Jiang, B. H.; Rue, E. A.; Semenza, G. L. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc. Natl. Acad. Sci. USA 1995, 92, 5510-5514.
24. Kaur, B.; Khwaja, F. W.; Severson, E. A.; Matheny, S. L.; Brat, D. J.; Van Meir, E. G. Hypoxia and the hypoxia-inducible-factor pathway in glioma growth and angiogenesis. Neuro-oncol. 2005, 7, 134-153.
25. Brat, D. J.; Kaur, B.; Van Meir, E. G. Genetic modulation of hypoxia induced gene expression and angiogenesis: relevance to brain tumors. Front. Biosci. 2003, 8, D100-D116.
26. Hernandez-Alcoceba, R.; Pihalja, M.; Qian, D.; Clarke, M. F. New oncolytic adenoviruses with hypoxia- and estrogen receptor-regulated replication. Hum. Gene Ther. 2002, 13, 1737-1750.
27. Cuevas, Y.; Hernandez-Alcoceba, R.; Aragones, J.; Naranjo-Suarez, S.; Castellanos, M. C.; Esteban, M. A.; Martin-Puig, S.; Landazuri, M. O.; Del Peso, L. Specific oncolytic effect of a new hypoxia-inducible factor-dependent replicative adenovirus on Von Hippel-Lindau-Defective renal cell carcinomas. Cancer Res. 2003, 63, 6877-6884.
28. Cho, W. K.; Seong, Y. R.; Lee, Y. H.; Kim, M. J.; Hwang, K. S.; Yoo, J.; Choi, S.; Jung, C. R.; Im, D. S. Oncolytic effects of adenovirus mutant capable of replicating in hypoxic and normoxic regions of solid tumor. Mol. Ther. 2004, 10, 938-949.
29. Post, D. E.; Devi, N. S.; Li, Z.; Brat, D. J.; Kaur, B.; Nicholson, A.; Olson, J. J.; Zhang, Z.; Van Meir, E. G. Cancer therapy with a replicating oncolytic adenovirus targeting the hypoxic microenvironment of tumors. Clin. Cancer Res. 2004, 10, 8603-8612.
30. Ambrosini, G.; Adida, C.; Altieri, D. C. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat. Med. 1997, 3, 917-921.
31. Tamm, I.; Wang, Y.; Sausville, E.; Scudiero, D. A.; Vigna, N.; Oltersdorf, T.; Reed, J. C. IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res. 1998, 58, 5315-5320.
32. Altieri, D. C. Validating survivin as a cancer therapeutic target. Nat. Rev. Cancer 2003, 3, 46-54.
33. Aoki, Y.; Feldman, G. M.; Tosato, G. Inhibition of STAT3 signaling induces apoptosis and decreases survivin expression in primary effusion lymphoma. Blood 2003, 101, 1535-1542.
34. Dan, H. C.; Jiang, K.; Coppola, D.; Hamilton, A.; Nicosia, S. V.; Sebti, S. M.; Cheng, J. Q. Phosphatidylinositol-3-OH kinase/AKT and survivin pathways as critical targets for geranyl-geranyltransferase I inhibitor-induced apoptosis. Oncogene 2004, 23, 706-715.
35. Sommer, K. W.; Schamberger, C. J.; Schmidt, G. E.; Sasgary, S.; Cerni, C. Inhibitor of apoptosis protein (IAP) survivin is upregulated by oncogenic c-H-Ras. Oncogene 2003, 22, 4266-4280.
36. Hoffman, W. H.; Biade, S.; Zilfou, J. T.; Chen, J.; Murphy, M. Transcriptional repression of the anti-apoptotic survivin gene by wild type p53. J. Biol. Chem. 2002, 277, 3247-3257.
37. Van Houdt, W. J.; Haviv, Y. S.; Lu, B.; Wang, M.; Rivera, A. A.; Ulasov, I. V.; Lamfers, M. L.; Rein, D.; Lesniak, M. S.; Siegal, G. P.; Dirven, C. M.; Curiel, D. T.; Zhu, Z. B. The human survivin promoter: A novel transcriptional targeting strategy for treatment of glioma. J . Neurosurg. 2006, 104, 583-592.
38. Balk, S. P.; Ko, Y. J.; Bubley, G. J. Biology of prostate-specific antigen. J. Clin. Oncol. 2003, 21, 383-391.
39. Cohen, P.; Peehl, D. M.; Graves, H. C.; Rosenfeld, R. G. Biological effects of prostate specific antigen as an insulin-like growth factor binding protein-3 protease. J. Endocrinol. 1994, 142, 407-415.
40. Kim, J.; Coetzee, G. A. Prostate specific antigen gene regulation by androgen receptor. J. Cell Biochem. 2004, 93, 233-241.
41. Rodriguez, R.; Schuur, E. R.; Lim, H. Y.; Henderson, G. A.; Simons, J. W.; Henderson, D. R. Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. Cancer Res. 1997, 57, 2559-2563.
42. Deweese, T. L.; Van Der Poel, H.; Li, S.; Mikhak, B.; Drew, R.; Goemann, M.; Hamper, U.; Dejong, R.; Detorie, N.; Rodriguez, R.; Haulk, T.; Demarzo, A. M.; Piantadosi, S.; Yu, D. C.; Chen, Y.; Henderson, D. R.; Carducci, M. A.; Nelson, W. G.; Simons, J. W. A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy. Cancer Res. 2001, 61, 7464-7472.
43. Yu, D. C.; Sakamoto, G. T.; Henderson, D. R. Identification of the transcriptional regulatory sequences of human kallikrein 2 and their use in the construction of calydon virus 764, an attenuated replication competent adenovirus for prostate cancer therapy. Cancer Res. 1999, 59, 1498-1504.
44. Yu, D. C.; Chen, Y.; Seng, M.; Dilley, J.; Henderson, D. R. The addition of adenovirus type 5 region E3 enables calydon virus 787 to eliminate distant prostate tumor xenografts. Cancer Res. 1999, 59, 4200-4203.
45. Small, E. J.; Carducci, M. A.; Burke, J. M.; Rodriguez, R.; Fong, L.; Van Ummersen, L.; Yu, D. C.; Aimi, J.; Ando, D.; Working, P.; Kirn, D.; Wilding, G. A phase I trial of intravenous CG7870, a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer. Mol. Ther. 2006, 14, 107-117.
46. Kelland, L. R. Overcoming the immortality of tumour cells by telomere and telomerase based cancer therapeutics - current status and future prospects. Eur. J. Cancer 2005, 41, 971-979.
47. Hahn, W. C.; Stewart, S. A.; Brooks, M. W.; York, S. G.; Eaton, E.; Kurachi, A.; Beijersbergen, R. L.; Knoll, J. H.; Meyerson, M.; Weinberg, R. A. Inhibition of telomerase limits the growth of human cancer cells. Nat. Med. 1999, 5, 1164-1170.
48. Lin, T.; Huang, X.; Gu, J.; Zhang, L.; Roth, J. A.; Xiong, M.; Curley, S. A.; Yu, Y.; Hunt, K. K.; Fang, B. Long-term tumor-free survival from treatment with the GFP-TRAIL fusion gene expressed from the hTERT promoter in breast cancer cells. Oncogene 2002, 21, 8020-8028.
49. Gu, J.; Zhang, L.; Huang, X.; Lin, T.; Yin, M.; Xu, K.; Ji, L.; Roth, J. A.; Fang, B. A novel single tetracycline-regulative adenoviral vector for tumor-specific Bax gene expression and cell killing in vitro and in vivo. Oncogene 2002, 21, 4757-4764.
50. Bilsland, A. E.; Anderson, C. J.; Fletcher-Monaghan, A. J.; Mcgregor, F.; Evans, T. R.; Ganly, I.; Knox, R. J.; Plumb, J. A.; Keith, W. N. Selective ablation of human cancer cells by telomerase-specific adenoviral suicide gene therapy vectors expressing bacterial nitroreductase. Oncogene 2003, 22, 370-380.
51. Gu, J.; Kagawa, S.; Takakura, M.; Kyo, S.; Inoue, M.; Roth, J. A.; Fang, B. Tumor-specific transgene expression from the human telomerase reverse transcriptase promoter enables targeting of the therapeutic effects of the Bax gene to cancers. Cancer Res. 2000, 60, 5359-5364.
52. Wirth, T.; Zender, L.; Schulte, B.; Mundt, B.; Plentz, R.; Rudolph, K. L.; Manns, M.; Kubicka, S.; Kuhnel, F. A telomerase-dependent conditionally replicating adenovirus for selective treatment of cancer. Cancer Res. 2003, 63, 3181-3188.
53. Zou, W.; Luo, C.; Zhang, Z.; Liu, J.; Gu, J.; Pei, Z.; Qian, C.; Liu, X. A novel oncolytic adenovirus targeting to telomerase activity in tumor cells with potent. Oncogene 2004, 23, 457-464.
54. Kyo, S.; Takakura, M.; Taira, T.; Kanaya, T.; Itoh, H.; Yutsudo, M.; Ariga, H.; Inoue, M. Sp1 cooperates with c-Myc to activate transcription of the human telomerase reverse transcriptase gene (hTERT). Nucleic Acids Res. 2000, 28, 669-677.
55. Kim, E.; Kim, J. H.; Shin, H. Y.; Lee, H.; Yang, J. M.; Kim, J.; Sohn, J. H.; Kim, H.; Yun, C. O. Ad-MTERT-delta19, a conditional replication-competent adenovirus driven by the human telomerase promoter, selectively replicates in and elicits cytopathic effect in a cancer cell-specific manner. Hum. Gene Ther. 2003, 14, 1415-1428.
56. Davis, J. J.; Wang, L.; Dong, F.; Zhang, L.; Guo, W.; Teraishi, F.; Xu, K.; Ji, L.; Fang, B. Oncolysis and suppression of tumor growth by a GFP-expressing oncolytic adenovirus controlled by an hTERT and CMV hybrid promoter. Cancer Gene Ther. 2006, 13, 720-723.
57. Peng, S. Y.; Lai, P. L.; Chu, J. S.; Lee, P. H.; Tsung, P. T.; Chen, D. S.; Hsu, H. C. Expression and hypomethylation of alpha-fetoprotein gene in unicentric and multicentric human hepatocellular carcinomas. Hepatology 1993, 17, 35-41.
58. Chen, H.; Egan, J. O.; Chiu, J. F. Regulation and activities of alpha-fetoprotein. Crit. Rev. Eukar. Gene 1997, 7, 11-41.
59. Li, Y.; Yu, D. C.; Chen, Y.; Amin, P.; Zhang, H.; Nguyen, N.; Henderson, D. R. A hepatocellular carcinoma-specific adenovirus variant, CV890, eliminates distant human liver tumors in combination with doxorubicin. Cancer Res. 2001, 61, 6428-6436.
60. Kim, J.; Lee, B.; Kim, J. S.; Yun, C. O.; Kim, J. H.; Lee, Y. J.; Joo, C. H.; Lee, H. Antitumoral effects of recombinant adenovirus YKL-1001, conditionally replicating in alpha-fetoprotein-producing human liver cancer cells. Cancer Lett. 2002, 180, 23-32.
61. Ye, X.; Liang, M.; Meng, X.; Ren, X.; Chen, H.; Li, Z. Y.; Ni, S.; Lieber, A.; Hu, F. Insulation from viral transcriptional regulatory elements enables improvement to hepatoma-specific gene expression from adenovirus vectors. Biochem. Biophys. Res. Commun. 2003, 307, 759-764.
62. Ye, X.; Lu, Q.; Zhao, Y.; Ren, Z.; Ren, X. W.; Qiu, Q. H.; Tong, Y.; Liang, M.; Hu, F.; Chen, H. Z. Conditionally replicative adenovirus vector carrying trail gene for enhanced oncolysis of human hepatocellular carcinoma. Int. J. Mol. Med. 2005, 16, 1179-1184.
63. Pin, R. H.; Reinblatt, M.; Fong, Y. Utilizing alpha-fetoprotein expression to enhance oncolytic viral therapy in hepatocellular carcinoma. Ann. Surg. 2004, 240, 659-665; discussion 665-666.
64. Johnson, L. F. G1 events and the regulation of genes for S-phase enzymes. Curr. Opin. Cell Biol. 1992, 4, 149-154.
65. Sala, A. B-MYB, a transcription factor implicated in regulating cell cycle, apoptosis and cancer. Eur. J. Cancer 2005, 41, 2479-2484.
66. Nevins, J. R. The Rb/E2F pathway and cancer. Hum. Mol. Genet. 2001, 10, 699-703.
67. Chung, R. Y.; Saeki, Y.; Chiocca, E. A. B-myb promoter retargeting of herpes simplex virus gamma34.5 gene-mediated virulence toward tumor and cycling cells. J. Virol. 1999, 73, 7556-7564.
68. Nakamura, H.; Kasuya, H.; Mullen, J. T.; Yoon, S. S.; Pawlik, T. M.; Chandrasekhar, S.; Donahue, J. M.; Chiocca, E. A.; Chung, R. Y.; Tanabe, K. K. Regulation of herpes simplex virus gamma(1)34.5 expression and oncolysis of diffuse liver metastases by Myb34.5. J. Clin. Invest. 2002, 109, 871-882.
69. Dahlstrand, J.; Zimmerman, L. B.; McKay, R. D.; Lendahl, U. Characterization of the human nestin gene reveals a close evolutionary relationship to neurofilaments. J. Cell Sci. 1992, 103(Pt. 2), 589-597.
70. Pilkington, G. J. Cancer stem cells in the mammalian central nervous system. Cell Prolif. 2005, 38, 423-433.
71. Veselska, R.; Kuglik, P.; Cejpek, P.; Svachova, H.; Neradil, J.; Loja, T.; Relichova, J. Nestin expression in the cell lines derived from glioblastoma multiforme. BMC Cancer 2006, 6, 32.
72. Dahlstrand, J.; Collins, V. P.; Lendahl, U. Expression of the class VI intermediate filament nestin in human central nervous system tumors. Cancer Res. 1992, 52, 5334-5341.
73. Sugawara, K.; Kurihara, H.; Negishi, M.; Saito, N.; Nakazato, Y.; Sasaki, T.; Takeuchi, T. Nestin as a marker for proliferative endothelium in gliomas. Lab. Invest. 2002, 82, 345-351.
74. Kambara, H.; Okano, H.; Chiocca, E. A.; Saeki, Y. An oncolytic HSV-1 mutant expressing ICP34.5 under control of a nestin promoter increases survival of animals even when symptomatic from a brain tumor. Cancer Res. 2005, 65, 2832-2839.
75. Toda, M.; Iizuka, Y.; Yu, W.; Imai, T.; Ikeda, E.; Yoshida, K.; Kawase, T.; Kawakami, Y.; Okano, H.; Uyemura, K. Expression of the neural RNA-binding protein musashi1 in human gliomas. Glia 2001, 34, 1-7.
76. Kanemura, Y.; Mori, K.; Sakakibara, S.; Fujikawa, H.; Hayashi, H.; Nakano, A.; Matsumoto, T.; Tamura, K.; Imai, T.; Ohnishi, T.; Fushiki, S.; Nakamura, Y.; Yamasaki, M.; Okano, H.; Arita, N. Musashi1, an evolutionarily conserved neural RNA-binding protein, is a versatile marker of human glioma cells in determining their cellular origin, malignancy, and proliferative activity. Differentiation 2001, 68, 141-152.
77. Imai, T.; Tokunaga, A.; Yoshida, T.; Hashimoto, M.; Mikoshiba, K.; Weinmaster, G.; Nakafuku, M.; Okano, H. The neural RNA-binding protein Musashi1 translationally regulates mammalian numb gene expression by interacting with its mRNA. Mol. Cell Biol. 2001, 21, 3888-3900.
78. Kanai, R.; Tomita, H.; Shinoda, A.; Takahashi, M.; Goldman, S.; Okano, H.; Kawase, T.; Yazaki, T. Enhanced therapeutic efficacy of G207 for the treatment of glioma through Musashi1 promoter retargeting of gamma34.5-mediated virulence. Gene Ther. 2006, 13, 106-116.
79. Gold, P.; Freedman, S. O. Specific carcinoembryonic antigens of the human digestive system. J. Exp. Med. 1965, 122, 467-481.
80. Hance, K. W.; Zeytin, H. E.; Greiner, J. W. Mouse models expressing human carcinoembryonic antigen (CEA) as a transgene evaluation of CEA-based cancer vaccines. Mutat. Res. 2005, 576, 132-154.
81. Hammarstrom, S. The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues. Semin. Cancer Biol. 1999, 9, 67-81.
82. Mullen, J. T.; Kasuya, H.; Yoon, S. S.; Carroll, N. M.; Pawlik, T. M.; Chandrasekhar, S.; Nakamura, H.; Donahue, J. M.; Tanabe, K. K. Regulation of herpes simplex virus 1 replication using tumor-associated promoters. Ann. Surg. 2002, 236, 502-512; discussion 512-513.
83. Pinkert, C. A.; Ornitz, D. M.; Brinster, R. L.; Palmiter, R. D. An albumin enhancer located 10 kb upstream functions along with its promoter to direct efficient, liver-specific expression in transgenic mice. Gene. Dev. 1987, 1, 268-276.
84. Miyatake, S.; Iyer, A.; Martuza, R. L.; Rabkin, S. D. Transcriptional targeting of herpes simplex virus for cell-specific replication. J. Virol. 1997, 71, 5124-5132.
85. Miyatake, S. I.; Tani, S.; Feigenbaum, F.; Sundaresan, P.; Toda, H.; Narumi, O.; Kikuchi, H.; Hashimoto, N.; Hangai, M.; Martuza, R. L.; Rabkin, S. D. Hepatoma-specific antitumor activity of an albumin enhancer/promoter regulated herpes simplex virus in vivo. Gene Ther. 1999, 6, 564-572.
86. Chung, Y. S.; Miyatake, S.; Miyamoto, A.; Miyamoto, Y.; Dohi, T.; Tanigawa, N. Oncolytic recombinant herpes simplex virus for treatment of orthotopic liver tumors in nude mice. Int. J. Oncol. 2006, 28, 793-798.
87. Li, X.; Zhang, J.; Gao, H.; Vieth, E.; Bae, K. H.; Zhang, Y. P.; Lee, S. J.; Raikwar, S.; Gardner, T. A.; Hutchins, G. D.; Vanderputten, D.; Kao, C.; Jeng, M. H. Transcriptional targeting modalities in breast cancer gene therapy using adenovirus vectors controlled by alpha-lactalbumin promoter. Mol. Cancer Ther. 2005, 4, 1850-1859.
88. Takahashi, K.; Nadal-Ginard, B. Molecular cloning and sequence analysis of smooth muscle calponin. J. Biol. Chem. 1991, 266, 13284-13288.
89. Yamamura, H.; Hashio, M.; Noguchi, M.; Sugenoya, Y.; Osakada, M.; Hirano, N.; Sasaki, Y.; Yoden, T.; Awata, N.; Araki, N.; Tatsuta, M.; Miyatake, S. I.; Takahashi, K. Identification of the transcriptional regulatory sequences of human calponin promoter and their use in targeting a conditionally replicating herpes vector to malignant human soft tissue and bone tumors. Cancer Res. 2001, 61, 3969-3977.
90. Acres, B.; Limacher, J. M. MUC1 as a target antigen for cancer immunotherapy. Exp. Rev. Vaccines 2005, 4, 493-502.
91. Abe, M.; Kufe, D. Characterization of cis-acting elements regulating transcription of the human DF3 breast carcinoma-associated antigen (MUC1) gene. Proc. Natl. Acad. Sci. USA 1993, 90, 282-286.
92. Kurihara, T.; Brough, D. E.; Kovesdi, I.; Kufe, D. W. Selectivity of a replication-competent adenovirus for human breast carcinoma cells expressing the MUC1 antigen. J. Clin. Invest. 2000, 106, 763-771.
93. Kasuya, H.; Pawlik, T. M.; Mullen, J. T.; Donahue, J. M.; Nakamura, H.; Chandrasekhar, S.; Kawasaki, H.; Choi, E.; Tanabe, K. K. Selectivity of an oncolytic herpes simplex virus for cells expressing the DF3/MUC1 antigen. Cancer Res. 2004, 64, 2561-2567.